Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Decitabine in NK/T-cell Lymphoma
NCT04279379Phase 2Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Beijing Tongren Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04279379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279379.